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Abstract
Background: Ulcerative colitis (UC) is associated with differential colonic
expression of genes involved in immune response (e.g. IL8) and barrier integrity
(e.g. cadherins). MicroRNAs (miRNAs) are regulators of gene expression and are
involved in various immune-related diseases. In this study, we investigated (1) if
miRNA expression in UC mucosa is altered and (2) if any of these changes
correlate with mucosal mRNA expression. Integration of mRNA and miRNA
expression profiling may allow the identification of functional links between
dysregulated miRNAs and their target mRNA.
Methodology: Colonic mucosal biopsies were obtained from 17 UC (10 active and
7 inactive) patients and 10 normal controls. Total RNA was used to analyze miRNA
and mRNA expression via Affymetrix miRNA 2.0 and Affymetrix Human Gene
1.0ST arrays, respectively. Both miRNA and gene expression profiles were
integrated by correlation analysis to identify dysregulated miRNAs with their
corresponding predicted target mRNA. Microarray data were validated with qRT-
PCR. Regulation of IL8 and CDH11 expression by hsa-miR-200c-3p was
determined by luciferase reporter assays.
Results: When comparing active UC patients vs. controls, 51 miRNAs and 1543
gene probe sets gave significantly different signals. In contrast, in inactive UC vs.
controls, no significant miRNA expression differences were found while 155 gene
probe sets had significantly different signals. We then identified potential target
genes of the significantly dysregulated miRNAs and genes in active UC vs. controls
and found a highly significant inverse correlation between hsa-miR-200c-3p and
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IL8, an inflammatory marker, and between hsa-miR-200c-3p and CDH11, a gene
related to intestinal epithelial barrier function. We could demonstrate that hsa-miR-
200c-3p directly regulates IL8 and CDH11 expression.
Conclusion: Differential expression of immune- and barrier-related genes in
inflamed UC mucosa may be influenced by altered expression of miRNAs.
Integrated analysis of miRNA and mRNA expression profiles revealed hsa-miR-
200c-3p for use of miRNA mimics as therapeutics.
Introduction
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease (IBD)
and is characterized by a diffuse mucosal inflammation extending proximally
from the rectum to a varying degree in the colon [1]. To date, it is widely accepted
that IBD is the result of an inadequate and ongoing activation of the mucosal
immune system to the luminal microbiota in genetically predisposed subjects.
This complex interaction of genetic, immune, and environmental factors causing
IBD is reflected in broad gene expression changes which can distinguish IBD from
controls. These gene expression changes include genes mainly involved in immune
response, cell adhesion, barrier integrity and tissue remodeling [2–4].
Gene expression is in part regulated by microRNAs (miRNAs), a group of small
(18–25 nucleotides), endogenous, single-stranded non-coding RNA molecules.
MiRNAs act as post-transcriptional negative regulators of gene expression by
directly binding to the 39-untranslated regions (UTRs) of specific target mRNAs,
which in turn will lead to degradation of the target mRNA or direct repression of
the translational process [5].
Aberrant miRNA expression has been linked to carcinogenesis. Evidence
suggests that miRNA expression profiles are more discriminating than profiles of
protein-coding mRNAs to classify similar human tumor types [6]. Recent studies
demonstrated that miRNAs also play an important role in regulating genes
involved in immune function [7]. Among these, miR-155-5p and miR-146-5p
were first identified as NF-kB regulatory key factors for innate and adaptive
immune responses [8, 9]. Since these early reports, it has been demonstrated that a
range of miRNAs display changes in their expression levels during inflammation
[10]. The evidence that miRNAs are important regulators of innate and adaptive
immune responses has encouraged research into the role of miRNAs in immune-
related diseases.
In IBD, single nucleotide polymorphisms (SNPs) located at miRNA binding
sites affect the expression of target mRNAs involved in disease pathogenesis
[11, 12]. Moreover, distinguished miRNA expression profiles have been described
in tissues of IBD patients with active and inactive disease [13–21]. In this study,
we hypothesized that altered expression of miRNAs may be involved in UC
pathogenesis and that some specific miRNAs could be potential biomarkers for
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PLOS ONE | DOI:10.1371/journal.pone.0116117 December 29, 2014 2 / 26
diagnosis of UC or disease activity. We therefore performed miRNA microarray
expression profiling on endoscopy-derived colonic biopsies from patients with
active UC, inactive UC and normal control subjects, to investigate the altered
miRNA expression in UC colonic mucosa. Gene expression analysis was
performed in parallel in a subgroup of UC patients and controls. The results of
both miRNA and gene expression profiles were integrated by correlation analysis
to identify dysregulated miRNAs with their corresponding predicted target
mRNA. This is the first study to correlate whole-genome mRNA and miRNA
profiling in UC mucosa. Further studies demonstrated that hsa-miR-200c-3p
directly regulates IL8 and CDH11 expression. This suggests that miRNAs with
altered expression in active UC mucosa regulate the expression of immune- and
barrier-related genes.
Materials and Methods
Ethics statement
This study was carried out at the University Hospital Gasthuisberg in Leuven. The
ethics committee of the University Hospital approved the study (S53684) and all
individuals gave written informed consent.
Patients and biopsy specimens
Colonic mucosal biopsies were obtained during colonoscopy from 17 UC patients
and from 10 controls. In UC patients, the biopsies were taken at the most affected
sites of the colon. Disease activity was defined using the Mayo endoscopic
subscore [22]. In this study, subscore 0 indicated inactive disease, and subscore 2
or 3 as active disease. Ten UC patients had active endoscopic disease and 7 UC
patients were in endoscopic remission. Additionally, colonic mucosal biopsies
were obtained from 5 active colonic Crohn’s disease (CDc) patients and from 5
patients with infectious or ischemic colitis (IC). Similar to UC patients, biopsies
were taken at the most inflamed part of the colon but at the edge of the ulcers.
Biopsies were immediately placed in RNAlater (Ambion, Austin, TX, USA) and
snap-frozen in liquid nitrogen prior to storage at -80 C˚. Remaining biopsies were
used for routine histopathological examination confirming diagnoses of (in)active
UC, active CD and ischemic colitis. In (in)active UC patients, histological disease
activity was evaluated using the Geboes score [23]. Haematoxylin-eosin stained
slides were scored ranging from grade 0 (structural change only) to grade 5
(erosion or ulceration), by a pathologist (GDH) blinded to endoscopic scores. All
active UC patients showed a moderate to severe histological score ranging from
grade 3.1 to grade 5.4 (median grade 5.2). Six out of 7 UC patients in remission
had mild or no structural abnormalities (grade 0.0 or 0.1), and 1 inactive UC
patient showed a mild increase of chronic inflammatory infiltrate (grade 1.1). This
indicates that the majority of inactive UC patients in this study are in ‘‘histologic
deep remission’’. Infectious colitis (3 cases of Clostridium difficile and 1 case of
miRNA and mRNA Mucosal Expression in UC
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Entamoeba histolytica) were confirmed by microbiological analysis of fecal
samples. We also studied a control group of 10 individuals with normal colonic
mucosa who underwent colonoscopy for colorectal cancer or polyp screening (5
male; median age, 57.7 y; range 51.9–62.6 y). Baseline characteristics of the UC,
CDc, IC patients and controls were comparable with regard to sex, age and body
mass index (Table 1). For continuous variables, two groups were compared
according to the Mann-Whitney U-test and using one-way analysis of variance
(ANOVA) when more than 2 groups had to be compared. Chi-Square or, when
appropriate, Fisher’s exact test was used to compare categorical variables. These
statistical tests were performed with SPSS software (version 20, Chicago, IL, USA).
miRNA isolation
For miRNA expression analysis, total RNA, including small RNA, was isolated
from the biopsies of UC, CDc, IC patients and controls with the mirVana miRNA
Isolation kit (Ambion), according to the manufacturer’s instructions. The
integrity and quantity of total RNA which includes small RNA was assessed with a
NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington,
DE, USA) and a 2100 Bioanalyzer (Agilent, Waldbronn, Germany) using the
Agilent RNA 6000 Nano kit and the Agilent Small RNA kit, respectively. All
samples showed good RNA quality (260/280 nm absorbance ratios .1.9 and RNA
Integrity Number (RIN).7).
miRNA microarray hybridization
To assess miRNA expression in colonic mucosa of active UC, inactive UC patients
and controls, total RNA, including a fraction of small RNA, was used and
analyzed with Affymetrix GeneChip miRNA 2.0 arrays (Affymetrix, Santa Clara,
CA, USA) containing 4560 probe sets for human small RNAs. Out of these probe
sets the 1082 probe sets of human mature miRNAs were filtered. These probe sets
guarantee 100% coverage of all human mature miRNAs in miRBase v.15 (April,
2010). Probe sets that were deleted in a more recent version of miRBase were
excluded for analysis. All steps of the procedure were performed according to the
Affymetrix standardized protocol for miRNA 2.0 arrays. Briefly, 250 ng of total
RNA was poly-A tailed, followed by ligation of the biotin-labeled molecule, using
the FlashTag Biotin HSR RNA Labeling Kit (Genisphere, Hatfield, PA, USA). To
verify the labeling efficiency, an ELOSA QC Assay (Genisphere) was run prior to
array hybridization, as recommended in the Genisphere protocol. A hybridization
cocktail was added to the biotin-labeled RNA sample and heated to 99 C˚ for
5 minutes and then to 45 C˚ for another 5 minutes. This mixture was injected into
an Affymetrix miRNA 2.0 array and hybridization was performed under rotation
at 48 C˚ for 16 hours. After washing and staining steps using the Affymetrix
Fluidics Station, the arrays were scanned on the Affymetrix 3000 GeneScanner.
Intensity values for each probe cell (.cel file) were calculated using Affymetrix
GeneChip Command Console (AGCC). Quality control of the microarray was
miRNA and mRNA Mucosal Expression in UC
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performed with the Affymetrix miRNA QC Tool, version 1.1.1.0. The miRNA
expression microarray data were deposited according to minimum information
about a microarray experiment (MIAME) guidelines to the Gene Expression
Omnibus database (series accession number GSE48957).
mRNA microarray hybridization
For gene expression analysis, total RNA was isolated from adjacent biopsies of a
subset of active and inactive UC patients, IC patients and controls using the
RNeasy Mini Kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s
instructions. RNA quality and quantity were assessed with a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies) and a 2100 Bioanalyzer (Agilent)
using the Agilent RNA 6000 Nano kit.
To assess gene expression in colonic mucosa of active UC, inactive UC patients
and controls, total RNA (150 ng), without small RNA fraction, was analyzed with
Affymetrix GeneChip Human Gene 1.0ST arrays. All steps were performed
according to Affymetrix manufacturer’s manual 4425209 Rev.B (Affymetrix), and
as described earlier by Breynaert et al. [24]. Quality assessment and outlier
Table 1. Baseline characteristics.
Baseline characteristic Active UC (n510)
Inactive UC
(n57) Active CDc (n55) IC (n55) Controls (n510) p-value
Male/female (%) 6/4 (60.0/40.0) 4/3 (57.1/42.9) 2/3 (40.0/60.0) 1/4 (20.0/80.0) 5/5 (50.0/50.0) 0.64
Median (IQR) age (years) 55.0 (45.3–61.3) 51.1 (36.1–60.4) 45.9 (36.1–60.1) 69.1 (68.2–78.4) 57.7 (51.9–62.6) 0.35
Median (IQR) BMI 27.3 (23.1–29.7) 26.0 (22.7–26.5) 27.1 (20.2–30.4) 21.5 (19.7–22.1) 26.3 (22.4–29.4) 0.46
Median (IQR) duration of disease
(years)
7.1 (0.6–20.1) 6.6 (4.0–14.4) 9.8 (7.6–15.0) NA NA 0.94
Extent of disease
left-sided colitis (%) 9 (90.0) 6 (85.7) NA NA NA 1
pancolitis (%) 1 (10.0) 1 (14.3) NA NA NA 1
colitis (%) NA NA 4 (80.0) NA NA NA
ileo-colitis (%) NA NA 1 (20.0) NA NA NA
Median (IQR) C-reactive protein (mg/
dL)
4.1 (2.6–16.2) 1.6 (0.6–2.9) 2.9 (1.5–5.7) 6.1 (5.5–13.2) NA 0.54
Concomitant medication
5-Aminosalicylates (%) 9 (90.0) 5 (71.4) 3 (60.0) NA NA 0.39
Corticosteroids (%) 4 (40.0) 0 (0.0) 2 (40.0) NA NA 0.15
Azathioprine (%) 0 (0.0) 1 (14.3) 0 (0) NA NA 0.30
Methotrexate (%) 0 (0.0) 0 (0.0) 1 (20.0) NA NA 0.17
Biologics (%) 1 (10.0) 0 (0.0) 0 (0) NA NA 0.53
Active smoking (%) 1 (10.0) 2 (42.9) 1 (20.0) 1 (20.0) NA 0.81
Average (SD) total Mayo score 8 (¡1.5) 0 (¡0.5) NA NA NA 0.001
Median (IQR) histological Geboes
score
5.2 (4.1–5.3) 0.0 (0.0–0.1) NA NA NA ,0.001
IQR: interquartile range; BMI: body mass index; SD: standard deviation.
doi:10.1371/journal.pone.0116117.t001
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detection was performed before and after normalization using the Bioconductor
package arrayQualityMetrics [25]. The mRNA expression microarray data were
deposited in MIAME format to the Gene Expression Omnibus database (series
accession number GSE48958).
Microarray expression data Analysis
The microarray data were analyzed as previously described by our group
[24, 26, 27]. The Affymetrix raw data (.cel files) were normalized using the robust
multichip average (RMA) algorithm [28], obtained from Bioconductor packages
in R (version 2.15.0, http://www.r-project.org). GeneChip Human Gene 1.0ST
arrays were processed using the R based aroma.affymetrix package (http://www.
aroma-project.org/) [29]. The LIMMA package [30] was used for the
identification of differentially expressed gene and miRNA probe sets between UC
patients and controls. Obtained p-values were adjusted for multiple testing using
the false discovery rate (FDR) method of Benjamini-Hochberg (B–H) [31]. Probe
sets were considered as biologically significant if showing a .2 fold change (FC)
and a FDR,0.05. Probe set annotations of gene probe sets were obtained through
the Affymetrix NetAffx website (NetAffx release 33.2, http://www.affymetrix.com/
analysis/index.affx) or the NCBI website (http://www.ncbi.nlm.nih.gov).
Annotations of miRNA probe sets were derived from the Sanger miRBase
database v.20 (June 2013, http://mirbase.org).
Unsupervised hierarchical clustering was applied to the microarray expression
profiles, using complete linkage and Euclidian distance as a similarity metric, to
visualize similarities among probe sets/samples. Both resulting dendrograms were
combined in a two-dimensional heat map with color intensities according to the
pattern of gene or miRNA expression. The Bio Functional Analysis tool in the
Ingenuity Pathway Analysis program (Ingenuity Systems; http://www.ingenuity.
com) was performed to identify the main biological functions associated to the
dataset of differentially expressed gene probe sets.
Integrated analysis of miRNA and mRNA expression
Predicted target mRNAs for the differentially expressed miRNAs were identified
using the miRWalk software tool (http://www.ma.uniheidelberg.de/apps/zmf/
mirwalk/) which allows simultaneous searches of several prediction programs
[32]. Five databases of predicted target mRNAs were selected: miRanda, miRDB,
miRWalk, RNA22 and TargetScan. Because no program is consistently superior to
all others and in order to reduce the probability of introducing false positives and/
or negatives as much as possible, we selected the potential targets that were
identified by at least three databases [18, 33]. Predicted targets of some alternative
mature miRNAs were only included in miRanda and miRWalk. In these cases,
Diana-microT was added as additional database to increase the probability of the
target prediction. Only targets predicted by two out of three databases were
selected as potential target mRNA of these alternative mature miRNAs.
miRNA and mRNA Mucosal Expression in UC
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In a second step we filtered out the mRNAs that were differentially expressed in
active UC vs. controls in the list of potential targets. Assuming an inverse
correlation between miRNA and mRNA expression levels, we selected the
dysregulated target mRNAs with an inverse correlation of expression with the
respective miRNA [34]. In a last step we specifically focused on groups of genes
with a clinical interest in UC pathogenesis and performed the Spearman rank
order correlation test to examine correlation relationships between each miRNA
and its computationally predicted target mRNA (SPSS, v.20). A significance
threshold of 0.05 was assessed to determine the significance of inverse correlation.
To correct for multiple testing, the FDR was estimated from the p-values using the
method of Benjamini and Hochberg (B–H) [31].
Quantitative Real-time Reverse-transcription Polymerase Chain
Reaction (qRT-PCR) of miRNA
The miRNA microarray expression data was confirmed by performing qRT-PCR
for hsa-miR-200c-3p and 10 other differentially expressed miRNAs selected
because of their highly significant p-value or fold change (hsa-miR-21-5p, hsa-
miR-31-5p, hsa-miR-146a-5p, hsa-miR-155-5p, hsa-miR-196b-5p, hsa-miR-
196b-3p, hsa-miR-200b-3p, hsa-miR-375, hsa-miR-422a and hsa-miR-650). Some
of these miRNAs have been described earlier in the literature as differentially
expressed in UC. Total RNA, including small RNA, from UC, CDc, IC patients
and controls, was reversely transcribed into cDNA using the miRCURY LNA
Universal RT microRNA PCR System (Exiqon, Vedbaek, Denmark). The reverse
transcription was performed using 20 ng of total RNA at 42 C˚ for 60 min
followed by heat-inactivation of the reverse transcriptase for 5 min at 95 C˚. cDNA
samples were diluted 1:80 in nuclease-free water and qRT-PCR was performed in
a final reaction volume of 10 ml using SYBR Green master mix and specific LNA
miRNA primers (Exiqon), according to the manufacturer’s instructions. Samples
were run in duplicate on a 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). The relative amount of each miRNA was calculated as a
ratio to the amount of SNORD44, a ubiquitously expressed small nucleolar RNA,
using the 22DDCT method. Results were analyzed using the Mann-Whitney U-test
(SPSS, v.20). A p-value of 0.05 was considered significant.
Quantitative Real-time Reverse-transcription Polymerase Chain
Reaction (qRT-PCR) of mRNA
To validate the mRNA microarray data, qRT-PCR was performed for selected
differentially expressed mRNAs: target genes cadherin 11 (CDH11) and
interleukin 8 (IL8), 5 differentially expressed mRNAs with a highly significant p-
value (SLC6A14, PDZD3, AQP8, CD55 and CDH3) and b-actin, which was used
as the endogenous reference gene.
From UC, IC patients and controls, cDNA was synthesized from 500 ng of total
RNA using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas,
miRNA and mRNA Mucosal Expression in UC
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St. Leon-Rot, Germany). qRT-PCR was performed with the appropriate TaqMan
Gene Expression Assay (Applied Biosystems). All assays were run in a final
reaction volume of 20 ml using the TaqMan Fast Universal PCR Master Mix
(Applied Biosystems) on the Applied Biosystems 7500 Fast Real-Time PCR
System. All samples were amplified in duplicate reactions. Relative mRNA
expression levels were calculated as 22DDCT using b-actin as reference mRNA.
Results were analyzed using the Mann-Whitney U-test (SPSS, v.20). A p-value of
0.05 was considered significant.
Cell Culture
Human colonic epithelial HT-29 cells were obtained from ECACC (European
Collection of Cell Cultures) and cultured in RPMI-1640 (Lonza, Basel,
Switzerland) that was supplemented with 10% fecal bovine serum and 1%
penicillin/streptomycin (Invitrogen, Merelbeke, Belgium) at 37 C˚ in a 5% CO2
incubator.
IL8 and CDH11 39UTR Construct Transfection and Luciferase
Reporter Assay
The 39UTRs of IL8 (corresponding to 462–1702 nucleotides of RefSeq
NM_000584.3) and CDH11 (corresponding to 2878–3619 nucleotides of RefSeq
NM_001797.2) were amplified by PCR from cDNA of HT-29 cells and cloned into
the XbaI site downstream of the luciferase coding sequence in the pGL3 reporter
vector (Promega, Madison, WI, USA). Mutations in the hsa-miR-200c-3p seed
regions of the IL8 and CDH11 39UTRs were generated using the QuikChange II
Site-Directed Mutagenesis kit (Agilent), according to the manufacturer’s
instructions with one modification: LA Taq DNA polymerase (TaKaRa, Kyoto,
Japan) was used instead of PfuUltra DNA polymerase. For each miRNA binding
site within the wild-type (WT) 39UTR, 5 nucleotides in the seeding region were
substituted. The site-specific mutations were confirmed by DNA sequencing. All
used primer sequences are available upon request.
HT-29 cells were plated in 24-well dishes overnight before transfection
(1.56105 cells per well). Cells were transfected with luciferase reporter constructs
(500 ng/well) using Lipofectamine 3000 (Invitrogen) according to the manu-
facturer’s protocol. To correct for transfection efficiency, 25 ng of a b-
galactosidase expression plasmid (pCMV-b-gal; Agilent) was used as an internal
control. Forty-eight hours after transfection, cells were lysed in 75 ml Passive Lysis
Buffer (Promega) and luciferase activities of the cell lysates were measured in a
Luminoskan Ascent luminometer (Thermo Labsystems, Franklin, MA, USA)
using the Promega Luciferase Assay Reagent. b-galactosidase activities of the same
samples were measured using the Galacto-Light Chemiluminescent Reporter Gene
Assay System (Tropix Inc., Bedford, MA, USA). Each transfection assay was
performed in triplicate and data represents three independent experiments. The
luciferase value of each sample was normalized to its b-galactosidase activity.
miRNA and mRNA Mucosal Expression in UC
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Differences in luciferase activity were analyzed by 2-tailed Student’s t test and a p-
value of 0.05 was considered significant (SPSS, v.20).
Transfection of miRNA Inhibitor
HT-29 cells were plated into 24-well dishes at 1.56105 cells and incubated
overnight. Various concentrations (5, 10 or 20 nM) of hsa-miR-200c-3p LNA
Power Inhibitor (anti-miR-200c-3p) or negative control LNA Power Inhibitor
(Exiqon) were transfected after 24 hours using Lipofectamine 3000 (Invitrogen)
and the transfected cells were incubated for 48 hours. Total RNA, including
miRNA, was isolated from the cells (see paragraph ‘miRNA isolation’) and stored
at -80 C˚ for qRT-PCR analysis of miR-200 family members hsa-miR-200b-3p and
hsa-miR-429.
In a second series of experiments, HT-29 cells were co-transfected with
luciferase vectors (original luciferase vector, luciferase vector containing WT
39UTR, or luciferase vector containing mutant 39UTR), 10 nM of either anti-miR-
200c-3p or negative control, and pCMV-b-gal as internal control, using
Lipofectamine 3000 (Invitrogen). After 48 hours, luciferase and b-galactosidase
activity were measured as described above. Each transfection assay was performed
in triplicate and data represent three independent experiments. Differences
between groups were determined using 2-tailed Student’s t tests (SPSS, v.20). A p-
value of 0.05 was considered significant.
Results
1. Differentially expressed miRNAs in UC vs. controls
Unsupervised cluster analysis of the top 20 probe sets encoding miRNAs with the
highest variation in expression across the 27 samples clearly identified two major
clusters (Fig. 1). Cluster I included all the controls, all 7 inactive UC patients and
only 1/10 active UC patient, and cluster II contained 9/10 active UC patients.
These findings indicate distinctive miRNA expression profiles based on colonic
inflammatory load.
MiRNA expression profiles were then compared between the different groups.
If we compared the miRNA expression profiles of all UC patients vs. normal
controls, four mature miRNAs were significantly differentially expressed: hsa-
miR-675-5p was significantly upregulated in UC vs. controls, while hsa-miR-378a-
5p, hsa-miR-196b-5p and hsa-miR-10b-5p were significantly downregulated. We
identified 51 (24 up- and 27 downregulated) mature miRNAs that were
significantly differentially expressed in active UC vs. controls (S1 Table), while no
significant differences were observed between inactive UC and controls.
Comparison of the miRNA expression profiles between active UC and inactive UC
identified 27 miRNAs (16 up- and 11 downregulated) that were significantly
different, with 24 miRNAs common to the significant miRNAs between active UC
and controls (Fig. 2). These results substantiate the different clusters observed by
miRNA and mRNA Mucosal Expression in UC
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the unsupervised clustering analysis, suggesting distinctive miRNA expression
profiles based on inflammatory activity.
2. Differentially expressed mRNAs in UC vs. controls
We also investigated the mRNA expression profile of a subset of the same patients
for which the miRNA expression profile was examined (7 active UC, 6 inactive
UC patients and 8 controls). Unsupervised cluster analysis of the top 20 probe sets
encoding mRNAs with the highest variation in expression across the 21 samples
showed two major clusters (Fig. 3). Cluster I includes all the active UC patients,
Fig. 1. Heatmap of miRNA expression in mucosal colonic biopsies of UC patient and control cohorts. Unsupervised hierarchical clustering of all
samples based on the log2 expression values of the top 20 most variable miRNAs. Samples are shown in the columns and miRNAs in the rows. The boxes
in color indicate the log2 intensities of the miRNAs, with blue indicating low expression and yellow indicating high expression.
doi:10.1371/journal.pone.0116117.g001
miRNA and mRNA Mucosal Expression in UC
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while cluster II contains all inactive UC patients and all controls. Comparable with
the findings of the miRNA expression data, this indicates distinctive mRNA
expression profiles based on degree of inflammation.
Second, mRNA expression profiles of active UC, inactive UC patients and
controls were compared. In active UC vs. controls, we identified 1543 significantly
differentially expressed probe sets (976 up- and 567 downregulated) representing
1288 annotated genes (S2 Table). After comparison of inactive UC vs. controls,
155 significantly differentially expressed gene probe sets (73 up- and 82
downregulated) were observed. Between active UC and inactive UC 991 gene
probe sets (796 up- and 195 downregulated) were significantly different (S1 Fig.).
These results substantiate the different clusters observed by the unsupervised
clustering analysis, suggesting distinctive miRNA expression profiles based on
inflammatory activity.
A Bio-Functional Analysis tool in the IPA program was performed on the
differentially expressed gene probe sets from the comparative analysis between
active UC patients and controls to identify which biological functions are
associated. The mRNAs encode proteins that were predominantly involved in the
following immune-related biological functions: cellular movement, immune cell
trafficking, hematological system development and function, cell-to-cell signaling
and interaction, and humoral immune response (S2 Fig.). In contrast, the
differentially expressed gene probe sets from the comparison between inactive UC
and controls encode proteins that are associated with cellular metabolism (lipid
Fig. 2. Venn diagram of the overlap of miRNA profiles in comparative analyses between (in)active UC and controls. The differentially expressed
miRNAs in the comparative analyses active UC vs. controls and active UC vs. inactive UC are depicted in two overlapping circles. An overlap of 24 miRNAs
(14 up- and 10 downregulated) was observed between both analyses.
doi:10.1371/journal.pone.0116117.g002
miRNA and mRNA Mucosal Expression in UC
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metabolism, cellular development, connective tissue development and function.
S3 Fig.).
3. Correlation between expression levels of significantly
differentially expressed miRNAs and their predicted target
mRNAs
In order to identify target mRNAs of one or more of the differentially expressed
miRNAs which potentially play a role in UC pathogenesis, we applied two
Fig. 3. Heatmap of mRNA expression in mucosal colonic biopsies of UC patient and control cohorts. Unsupervised hierarchical clustering of all
samples based on the log2 expression values of the top 20 most variable mRNAs. Samples are shown in the columns and mRNAs in the rows. The boxes in
color indicate the log2 intensities of the mRNAs, with blue indicating low expression and yellow indicating high expression.
doi:10.1371/journal.pone.0116117.g003
miRNA and mRNA Mucosal Expression in UC
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selections of the potential targets. The target mRNAs should be: (1) differentially
co-expressed together with the altered miRNAs in the inflamed colonic mucosa of
UC patients; and (2) have an inverse correlation of expression with the miRNA by
which it is targeted. This resulted in 3328 pairs of significantly altered miRNAs
and predicted target mRNAs with an inverse correlation of expression in active
UC vs. controls (S3 Table). More than 60% (806/1288) of the altered annotated
genes are potentially regulated by one or more of the 51 altered miRNAs in active
UC vs. controls. The Bio-Functional Analysis tool in the IPA program was used to
assign biological functions to the putative target mRNAs. The mRNAs encode
proteins that were predominantly involved in the biological functions: cellular
movement, immune cell trafficking, hematological system development and
function, tissue morphology and cellular development (S4 Fig.). All of these
miRNA-regulated biological pathways are related to the pathogenesis of UC.
Of all miRNA-mRNA pairs, we selected the genes with an interesting role in UC
pathogenesis: UC susceptibility genes [35], anti-microbial peptides [2], cell-
adhesion molecules [3] and genes related to the intestinal epithelial barrier
function (S4 Table). Hence, we ended up with a list of 357 miRNA – target
mRNA pairs with clinical interest in UC. We detected a significant correlation in
318 miRNA-mRNA pairs (S5 Table). Four of the top 10 most significantly
inversely correlated miRNA – target mRNA pairs are related to one specific
miRNA, hsa-miR-200c-3p (Table 2). This miRNA was chosen to validate using
qRT-PCR, together with two target mRNAs of interest: IL8, a UC susceptibility
gene, and CDH11, a gene related to intestinal barrier function (Fig. 4).
4. Validation of the microarray expression data by qRT-PCR
Based on the correlation analysis of miRNA and mRNA expression, the
significance levels of miRNA and mRNA microarray data and previous literature,
11 miRNAs and 7 mRNAs were chosen to confirm their altered expression in
active UC compared to controls by qRT-PCR. Consistent with the microarray
data, we were able to confirm that 5 miRNAs (hsa-miR-21-5p, hsa-miR-31-5p,
hsa-146a-5p, hsa-miR-155-5p and hsa-miR-650) were significantly increased in
active UC mucosa, whereas 3 miRNAs (hsa-miR-196b-5p, hsa-miR-196b-3p and
hsa-miR-200c-3p) were significantly decreased, as compared with controls.
Remarkably, although initially identified in the microarray analysis as significantly
downregulated, we identified a significant upregulation of hsa-miR-375 in active
UC patients vs. controls. Relative expression levels of these 9 miRNAs are depicted
in Fig. 5. qRT-PCR did not confirm the differential expression of hsa-miR-200b-
3p in active UC compared to controls. Expression of hsa-miR-422a was
undetectable in all samples (data not shown). In inactive UC mucosa, all miRNAs
with altered expression in active UC had expression levels comparable to the levels
in normal controls, except for 1 miRNA: hsa-miRNA-196b-5p. Similarly to active
UC, expression of this miRNA was downregulated in inactive UC compared to
controls. To assess the specificity of the miRNA expression alterations in UC
tissue, we determined the expression of 9 miRNAs in mucosa of patients with
miRNA and mRNA Mucosal Expression in UC
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active CDc and IC. All 6 miRNAs (hsa-miR-21-5p, hsa-miR-31-5p, hsa-146a-5p,
hsa-miR-155-5p, hsa-miR-375 and hsa-miR-650) with increased expression in
active UC demonstrated a similar upregulated expression profile in both active
CDc and IC compared to healthy controls. However, 2 miRNAs (hsa-miR-196b-
5p and hsa-miR-200c-3p) with decreased expression in active UC were
significantly upregulated in IC compared to both active UC and controls. These
results indicate that the miRNA expression profile of active UC mucosa is distinct
from inactive UC, IC and normal controls. Although, we could not identify
significant differences in miRNA expression between active UC and CDc,
indicating a similar miRNA expression profile in inflamed colonic mucosa in IBD
patients.
Differential expression of all 7 mRNAs could be confirmed. Expression of IL8,
CDH11, SLC6A14, CD55 and CDH3 was significantly increased, while AQP8 and
PDZD3 were significantly decreased in active UC compared to inactive UC and
Table 2. Top 10 most significantly correlated miRNA-mRNA pairs.
miRNAs Predicted target
Spearman correlation
coefficient p-value FDR
hsa-miR-200c-3p IL8 UC susceptibility gene 20.918 1.4261026 4.7261024
hsa-miR-200c-3p LRRK2 UC susceptibility gene 20.904 3.8861026 6.4661024
hsa-miR-200c-3p CALU UC susceptibility gene 20.893 7.4961026 7.4661024
hsa-miR-200a-5p FADS2 UC susceptibility gene 20.889 9.1961026 7.4661024
hsa-miR-141-3p IKZF1 UC susceptibility gene 20.886 1.1261025 7.4661024
hsa-miR-200c-3p CDH11 Barrier gene 20.879 1.6361025 7.7461024
hsa-miR-200b-5p CXCL9 Cell adhesion molecule 20.879 1.6361025 7.7461024
hsa-miR-141-3p PRDM1 UC susceptibility gene 20.875 1.9561025 7.7461024
hsa-miR-194-5p FADS2 UC susceptibility gene 20.871 2.3261025 7.7461024
hsa-miR-378a-5p FADS2 UC susceptibility gene 20.871 2.3261025 7.7461024
doi:10.1371/journal.pone.0116117.t002
Fig. 4. Scatter plot of expression levels of hsa-miR-200c-3p and its predicted target genes. Correlation between hsa-miR-200c-3p expression values
and IL8 (A) and CDH11 (B) expression values, with their respective Spearman correlation coefficient.
doi:10.1371/journal.pone.0116117.g004
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controls. In inactive UC, expression of SLC6A14, CDH3 and PDZD3 was
significantly different from controls. To check if the 7 gene expression alterations
are a marker for inflammation or specific for active UC, gene expression was also
measured in the biopsies of IC patients. As compared to controls, we identified a
significant upregulation of IL8, SLC6A14, CD55 and CDH3 and a significant
downregulation of AQP8 in IC patients. The fold change in expression of these 5
genes is significantly smaller in IC patients than in active UC patients, compared
to controls. This suggests that the alteration in expression of these 5 genes
probably reflect unspecific inflammation rather than events specific for UC.
However, expression of CDH11 and PDZD3 is not significantly different between
IC patients and controls. This indicates that alterations in expression of CDH11
and PDZD3 are part of a specific signature of active UC (Fig. 6).
5. Regulation of IL8 and CDH11 by hsa-miR-200c-3p in colonic
epithelial cells
Correlation analysis suggested a highly significant negative correlation between
expression levels of hsa-miR-200c-3p and its potential target mRNAs of interest:
IL8 and CDH11. To determine whether these mRNAs are targeted by endogenous
miRNAs, we transfected HT-29 cells with luciferase reporter vectors containing
the WT 39UTR (pGL3_IL8_WT and pGL3_CDH11_WT with putative binding
site for hsa-miR-200c-3p) or luciferase vector containing mutant 39UTR
Fig. 5. Validation of expression levels of 10 selected miRNAs in human colon. Boxplots of the expression level of hsa-miR-200c-3p and 9 other
significantly differentially expressed miRNAs in controls (n510), active UC (n510), inactive UC (n57), active CDc (n55) and IC (n55) patients, as assessed
by qRT-PCR (line, average; *p,0.05; ** p,0.01; *** p,0.001).
doi:10.1371/journal.pone.0116117.g005
miRNA and mRNA Mucosal Expression in UC
PLOS ONE | DOI:10.1371/journal.pone.0116117 December 29, 2014 15 / 26
(pGL3_IL8_mut and pGL3_CDH11_mut with mutations at the binding site)
(Fig. 7A). Compared to the original luciferase vector (pGL3), transfecting the
wild-type constructs pGL3_IL8_WT and pGL3_CDH11_WT resulted in .80%
and .50% reduction in relative luciferase activity, respectively (p,0.001)
(Fig. 7B). Mutating the binding site in the 39UTR of CDH11 resulted in a
restitution of the luciferase activity to the level of the original vector. This
indicates that endogenous hsa-miR-200c-3p can target the 39UTR of CDH11 and
hereby regulating its expression. However, mutations in the binding site of 39
UTR of IL8 did not restore the luciferase activity (Fig. 7B). Endogenous miRNAs,
excluding hsa-miR-200c-3p, can suppress the luciferase activity by targeting the
39UTR of IL8 at different binding sites.
Hsa-miR-200c-3p is part of the miR-200 family, where it shares the same seed
sequence with hsa-miR-200b-3p and hsa-miR-429. If a single miRNA is inhibited,
other miRNAs of the same family may show a compensatory effect. To test
whether this is true in HT-29 cells, varying concentrations of a synthetic specific
miRNA inhibitor (anti-miR-200c-3p) and negative control inhibitor were
transfected into the cells (Fig. 7C). Expression of hsa-miR-200b-3p and hsa-miR-
429 (both having the same seed sequence as hsa-miR-200c-3p) was assessed.
Compared to transfection with the negative control, miRNA expression of hsa-
miR-200b-3p and hsa-miR-429 significantly increased (FC51.9 and 2.3,
respectively) in the cells transfected with 5 nM of anti-miR-200c-3p, while
Fig. 6. Validation of expression levels of 7 selected mRNAs in human colon. Boxplots of the expression level of IL8, CDH11, SLC6A14, CD55, CDH3,
AQP8 and PDZD3 in controls (n58), active UC (n57), inactive UC (n56) and IC (n55) patients, as assessed by qRT-PCR (box, 25%–75%; whisker, 5%–
95%; *p,0.05; ** p,0.01).
doi:10.1371/journal.pone.0116117.g006
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expression significantly decreased (FC5-2.2 and -1.9, respectively) after
transfection with 20 nM. However, expression of both miR-200c family members
was not significantly affected after transfection with 10 nM anti-miR-200c-3p
(Fig. 7C). These results suggest that a concentration of 10 nM miRNA inhibitor
does not alter the expression of miRNA family members.
To verify that hsa-miR-200c-3p directly targets the 39UTR of IL8 and CDH11,
we co-transfected the luciferase vectors with a 10 nM of anti-miR-200c-3p or a
negative control inhibitor in HT-29 cells. In cells transfected with the negative
control, luciferase activity was decreased compared to the original luciferase
vector, because of endogenous miRNAs. The miR-200c-3p inhibitor restored the
relative luciferase activity of pGL3_IL8_WT and pGL3_CDH11_WT with 10%
and 30% respectively (p,0.01), indicating the binding of hsa-miR-200c-3p to the
Fig. 7. Luciferase reporter assay showing that hsa-miR-200c-3p regulates IL8 and CDH11 expression in HT-29 cells. (A.) Sequence alignments of
hsa-miR-200c-3p with the wild-type and mutant 39UTR of target mRNAs IL8 and CDH11, cloned into the pGL3 vector. Mutated nucleotides are underlined
(B.) The original pGL3 vector, vectors with wild-type 39UTRs and vectors with mutant 39UTRs were transfected into HT-29 cells and luciferase activity
(normalized to b-galactosidase activity) was quantified 48 h after transfection. (*** p,0.001, compared to pGL3-vector). (C.) Co-transfection of 10 nM of
anti-miR-200c-3p or negative control inhibitor with luciferase reporter vectors in HT-29 cells (** p,0.01, compared to pGL3-vector with negative control).
doi:10.1371/journal.pone.0116117.g007
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target 39UTRs. Luciferase activity of mutant vectors was not significantly different
after transfection with anti-miR-200c-3p or negative control (Fig. 7D). These
results indicate that IL8 and CDH11 are directly targeted by hsa-miR-200c-3p.
Discussion
Recently, several papers have focused on investigating altered expression of
miRNAs in IBD [36–38]. However, the majority of these studies only observed the
expression of a limited amount of miRNAs. Moreover, there is a lack of studies
integrating both miRNA and mRNA expression profiles in IBD. This study is the
first whole-genome miRNA and mRNA expression microarray profiling in UC
mucosa. Several studies have assumed that an inverse correlation between miRNA
and mRNA expression levels may reflect miRNA – target mRNA relationship.
Therefore, we performed a genome-wide analysis of both miRNA and mRNA
expression in colonic mucosal UC biopsies. This correlation analysis reveals a
useful approach to identify genes potentially targeted by dysregulated miRNAs.
Furthermore, we found evidence that these miRNAs can directly target genes
related to UC pathogenesis.
Hierarchical cluster analysis of both miRNA and mRNA expression profiles
allowed us to clearly identify two different clusters related to the inflammatory
load in the colonic mucosa. Comparative analysis between active UC patients and
controls identified 51 differentially expressed miRNAs and 1288 differentially
expressed annotated genes. More than half of these mRNAs are potentially
targeted by one or more of the dysregulated miRNAs. Both the complete list of
differentially expressed mRNAs as the subset of mRNAs which are potentially
targeted by altered miRNAs, are mainly involved in immune-related functions.
This result suggests a role of miRNAs in the regulation of gene expression in UC.
Our miRNA expression results identified several miRNAs that correspond with
those found in previous studies comparing miRNA profiles in colonic mucosa of
active UC patients vs. controls. The first study investigating this subject identified
11 miRNAs significantly differentially expressed in active UC mucosa vs. controls
[13]. We could confirm the upregulation of hsa-miR-21-5p and the down-
regulation of hsa-miR-192-5p. Wu et al. [13] identified the chemokine
macrophage inflammatory protein 2-a (MIP-2a or CXCL2) as target mRNA of
hsa-miR-192-5p. Here, we confirm the strong increase of MIP-2a expression in
active UC vs. controls (FC55.06), most likely due to the downregulation of hsa-
miR-192-5p (FC5-2.98). Takagi et al. also observed an upregulation of hsa-miR-
21-5p and hsa-miR-155-5p in active UC mucosa compared to controls [15]. We
could confirm the upregulation of 2 miRNAs (hsa-miR-31-5p and hsa-miR-223-
3p) out of 9 miRNAs that were identified as dysregulated in active UC mucosa by
Fasseu et al. Lin et al. identified 4 miRNAs with an increased expression in UC, of
which we could confirm the upregulation of hsa-miR-31-5p and hsa-miR-146a-
5p. The authors propose hsa-miR-31-5p as a diagnostic biomarker of IBD to
differentiate from its mimics, including IC [19]. Our study can’t confirm this
miRNA and mRNA Mucosal Expression in UC
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hypothesis because expression levels of hsa-miR-31-5p were elevated in both UC
and IC patients compared to controls. Min et al. identified 68 miRNAs
differentially expressed in active UC vs. controls [20]. Here, we could confirm the
upregulation of hsa-let-7i-5p, hsa-miR-21-5p, hsa-miR-146a-5p and hsa-miR-
155-5p, and the downregulation of hsa-miR-196b-5p, hsa-miR-200a-5p, hsa-
miR-200a-3p, hsa-miR-200c and hsa-miR-378a-3p. In a cohort of pediatric UC
patients, Zahm et al. identified 8 altered miRNAs in rectum of UC patients
compared to controls [21]. Dysregulation of 7 of these miRNAs coincides with
our results (upregulation of hsa-let-7i-5p, hsa-miR-21-5p and hsa-miR-146a-5p;
downregulation of hsa-miR-192-5p, hsa-miR-194-5p and hsa-miR-200b-3p).
Olaru et al. studied the miRNA expression in colonic biopsies of active IBD
patients vs. IBD-associated dysplasia [39]. They identified 10 up- and 22
downregulated miRNAs of which 3 miRNAs were upregulated and 13 miRNAs
were also downregulated in active UC vs. controls. The same authors also reported
a linear increase in expression of hsa-miR-31-5p along the evolution of normal
colon tissue, to IBD and to IBD-associated dysplasia [39]. Here, we confirm the
strong increase in expression of hsa-miR-31-5p in active UC vs. controls. Iborra
et al. reported hsa-miR-650 and hsa-miR-196b-5p as altered in active UC vs.
inactive UC at tissue level [17]. In this study, we confirm the strong upregulation
of hsa-miR-650 in active UC compared to both inactive UC (FC511.59) and
controls (FC513.69) and a downregulation of hsa-miR-196b-5p in active UC vs.
controls. Brest et al. demonstrated an upregulation of hsa-miR-196a/b-5p in the
inflamed mucosa of CD patients [11]. Remarkably, both hsa-miR-196a-5p and
hsa-196b-5p are downregulated in active UC vs. controls. Therefore, expression of
miR-196a/b-5p might be useful to differentiate UC from CDc. According to
published literature, few miRNAs are consistently dysregulated in active UC
mucosa compared to controls. Although, miRNAs such as hsa-miR-21-5p, hsa-
miR-31-5p or hsa-miR-155-5p are reported in several studies, and have potential
as biomarker. However, in this study these miRNAs showed a similar increased
expression in active UC as in active CDc and IC colonic tissue. Interestingly, we
showed a downregulation of hsa-miR-200c-3p in active UC and of hsa-miR-196b-
5p in both active and inactive UC mucosa compared to controls, while expression
of both miRNAs is upregulated in inflammatory controls. Therefore, hsa-miR-
200c-3p and/or hsa-miR-196b-5p show promise as a diagnostic biomarker of UC,
although further verification is needed.
The functional role of multiple significantly different miRNAs has already been
studied extensively. Three miRNAs (hsa-miR-155-5p, hsa-miR-21-5p, hsa-miR-
146a-5p) together regulate inflammation through regulation of the Toll-like
receptor (TLR) signaling pathway [40]. The inflammatory response is character-
ized by a continuous upregulation of hsa-miR-155-5p [8]. Furthermore, this
miRNA directly targets mRNAs coding for several proteins involved in
lipopolysaccharide (LPS) signaling while enhancing TNF-a translation [41].
Expression of hsa-miR-21-5p is important in the LPS-induced inflammatory
response, because it has an essential role in the regulation of the pro- (NF-kB) as
well as the anti-inflammatory (IL-10) response [42]. Also hsa-miR-146a-5p helps
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fine-tuning the immune response through a negative feedback regulation by direct
targeting of IRAK1 and TRAF6, two mediators of the TLR signaling pathway [9].
Involvement of this trio of miRNAs in active UC is confirmed as they are
upregulated in the comparison vs. controls. Moreover, in our study was hsa-miR-
155-5p the most significantly different miRNA (FDR52.2261025). Also other
significantly different miRNAs have interesting properties related to the immune
system. Epithelium-expressed hsa-miR-375 has an important role in epithelium
immune system by regulating goblet cell differentiation [43]. Regulation of host
gene expression by gut microbiota is mediated by hsa-miR-665 [44]. Hsa-miR-
223-3p is an essential modulator of myeloid differentiation and has a role in IL-
17-mediated inflammation [45], while hsa-miR-150-5p is upregulated during B-
and T-cell maturation [46]. We confirm the dysregulation of these miRNAs in
active UC and consequently their association with UC pathogenesis.
When comparing miRNA microarray expression levels of inactive UC patients
and controls, we found no significant miRNA expression differences between
inactive UC and controls. However, after measuring expression levels of hsa-miR-
196b-5p using qRT-PCR, we found a significant difference between both groups.
This could be explained by the fact that the statistical criteria used for defining
significance by qRT-PCR (Mann-Whitney p-value ,0.05) is less strict than the
criteria used for microarray data significance (.2-fold change and FDR,0.05).
Previous work has demonstrated significant differences in inactive UC patients vs.
controls [16]. However, that study investigated the miRNA expression in non-
inflamed tissue of UC patients with clinical and endoscopic active disease, whereas
we examined UC patients in clinical, endoscopic and histologic remission. Also
other publications report significant differences in miRNA expression in inactive
UC mucosa vs. controls [13, 18]. Though, no validated score for histological
inflammation was applied to the biopsies in these studies. Therefore, we
hypothesize the reason for these dissimilarities could be the more strict criteria for
patient selection or a difference in histopathological grades of UC activity.
Correlation analysis between miRNA and the predicted target mRNA
expression levels showed that 4 of the top 10 most significantly inversely
correlated miRNA – target mRNA pairs belong to hsa-miR-200c-3p. Of interest,
out of the four predicted target mRNAs are 3 UC susceptibility genes (IL8,
LRRK2, CALU) and the fourth gene is related to the intestinal barrier function
(CDH11). We confirmed the significant downregulation of hsa-miR-200c-3p and
significant upregulation of IL8 and CDH11 in active UC vs. controls using qRT-
PCR. Hsa-miR-200c-3p is known to be involved in innate immunity by regulating
the efficiency of TLR4 signaling through the MyD88-dependent pathway [47].
Additionally, members of the miR-200 family are involved in the epithelial to
mesenchymal transition (EMT) by regulating the E-cadherin transcriptional
repressors ZEB1 and SIP1 both in cancer [48, 49]and in IBD [50]. One miRNA of
this family, hsa-miR-200b-3p, is proposed as a diagnostic serum marker for
fibrosis in Crohn’s disease. Chen et al. suggest the potential role of hsa-miR-200b-
3p in inhibiting EMT and promoting the proliferation of intestinal epithelial cells.
miRNA and mRNA Mucosal Expression in UC
PLOS ONE | DOI:10.1371/journal.pone.0116117 December 29, 2014 20 / 26
Moreover, it could protect intestinal epithelial cells from fibrogenesis in vitro
[50, 51].
UC is characterized by a strong increase of IL8, a powerful neutrophil
chemoattractant and activator produced by endothelial cells, lamina propria
mononuclear cells and epithelial cells [52]. IL8 is a UC susceptibility gene, recently
discovered in the latest meta-analysis of IBD GWAS studies [35]. It is a key
marker in colonic inflammation, and therefore seems to be a reliable biomarker,
closely related to disease activity [53]. Interestingly, it has been shown that IL8
expression is indirectly regulated by hsa-miR-200c-3p by targeting IKBKB [54].
Also other miRNAs are involved in IL8 regulation like hsa-miR-155-5p by
lowering SHIP1 expression [55], and hsa-miR-146a/b-5p by negatively regulating
NF-kB activity [56]. In this study, we demonstrated that in UC hsa-miR-200c-3p
also directly regulates IL8 expression. This result is consistent with previous
localization studies in normal and UC mucosa, where it has been shown that hsa-
miR-200c-3p and IL8 are expressed in colonic epithelial cells [49, 57].
Previous microarray profiling studies in UC have already implicated a role for
CDH11, a type II classical cadherin that mediates fibroblast cell-cell adhesion, in
UC pathogenesis. Costello et al. have shown a significant upregulation of CDH11
in IBD, but not in inflamed non-IBD tissue. It is presumed this member of the
cadherin family could be involved in restructuring processes in the intestinal
mucosa [58]. Here, we confirm the specific role this gene might have in active UC
by the fact that CDH11 expression is not dysregulated in inflammatory controls
compared to controls. Using an integrated analysis of miRNA and mRNA
expression in breast cancer, Luo et al. recently identified CDH11 as a target gene
of hsa-miR-200c-3p [59]. In the present study, we demonstrated that CDH11 is
also targeted by hsa-miR-200c-3p in colonic epithelial cells. Downregulation of
CDH11 could serve as an interesting therapeutic goal in UC, potentially by the use
of a mimic of hsa-miR-200c-3p. In a dextran sodium sulfate-colitis mouse model,
CDH11 deficient mice are significantly protected from severe colitis compared to
wild-type mice [60]. This suggests that targeting CDH11 may be of interest in
IBD. In pulmonary fibrosis, expression of CDH11 is also increased in wound
healing and fibrotic skin. Anti-CDH11-neutralizing monoclonal antibodies
(mAb) successfully treated established pulmonary fibrosis in mice. Thus, CDH11
is a mediator in EMT and the development of pulmonary fibrosis [61].
Furthermore, in rheumatoid arthritis CDH11 modulates synovial fibroblasts to
evoke inflammatory factors and targeting CDH11 by mAb directed against
CDH11 significantly reduced inflammation [62]. Intestinal fibrosis can occur in
both CD as UC. Inflammation of the (sub)mucosal layers in UC can induce
fibrosis through EMT [63]. Being a mediator of EMT in the development of organ
fibrosis and a contributor to the inflammatory process in rheumatoid arthritis, it
could be hypothesized that CDH11 is a newly identified candidate therapeutic
target for fibrosis in IBD.
As a potential therapeutic, miRNAs have inherent advantages: they are
evolutionary conserved and due to their small size miRNAs are more resistant to
degradation. In a pathological condition, upregulated miRNAs can be decreased
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by potent oligonucleotides, ‘antagomirs’, that inhibit their miRNA targets by
binding with high affinity and specificity. Downregulated miRNAs can be
increased by using synthetic oligonucleotide miRNA mimics or miRNA
expression gene vectors [64]. Currently, several clinical trials are testing the
efficacy of these therapies. Recently, a phase 2a study for the use of miravirsen, an
antagomir that sequesters miR-122-5p, for treatment of hepatitis C infection was
successfully completed [65]. In chronic inflammatory diseases, miR-155-5p
antagonists show possible therapeutic value by modulating activation of
macrophages and the number of circulating granulocytic cells [66]. Potentially,
treatment with a synthetic mimic of miR-200c-3p in IBD could decrease
inflammation by counteracting the inflammatory action of IL8, or by down-
modulating the NF-kB response after TLR4 ligation. Moreover, this treatment
could inhibit EMT and prevent fibrosis in the pathogenesis of IBD.
In conclusion, this study represents an integrated analysis of miRNA and
mRNA expression in colonic mucosal UC biopsies. We identified a number of
miRNAs that are differentially expressed between active UC and controls,
supporting the hypothesis that altered expression of miRNAs plays a role in the
expression of immune-related (e.g. IL8) and barrier-related (e.g. CDH11) genes in
inflamed UC mucosa. Integrated analysis of miRNA and gene expression profiles
revealed potential targets, such as hsa-miR-200c-3p, for use of miRNA mimics as
therapeutics.
Supporting Information
S1 Fig. Venn diagram of the overlap of mRNA profiles in comparative analyses
between (in)active UC and controls. The differentially expressed mRNAs in the
comparative analyses between active UC, inactive UC and controls are depicted in
three overlapping circles.
doi:10.1371/journal.pone.0116117.s001 (TIF)
S2 Fig. Biological functions associated to active UC. Bar chart representing the top
10 most significant biological functions that were associated with the 1543
significantly differentially expressed probe sets in active UC vs. controls. The
functional categories are displayed along the x-axis and the y-axis indicates the
significance score.
doi:10.1371/journal.pone.0116117.s002 (TIF)
S3 Fig. Biological functions associated to inactive UC. Bar chart representing the
top 10 most significant biological functions that were associated with the
significantly differentially expressed probe sets in inactive UC vs. controls. The
functional categories are displayed along the x-axis and the y-axis indicates the
significance score.
doi:10.1371/journal.pone.0116117.s003 (TIF)
S4 Fig. Biological functions associated to predicted target mRNAs of dysregulated
miRNAs in active UC. Bar chart representing the top 10 most significant
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biological functions that were associated with the 3328 pairs of miRNAs and their
predicted target mRNAs that are altered in active UC vs. controls. The functional
categories are displayed along the x-axis and the y-axis indicates the significance
score.
doi:10.1371/journal.pone.0116117.s004 (TIF)
S1 Table. A list of all genes focused on in the present study because of clinical
interest in UC. The list contains 1227 UC susceptibility genes, 91 AMP proteins,
70 CAMs and 223 genes related to intestinal barrier.
doi:10.1371/journal.pone.0116117.s005 (XLSX)
S2 Table. miRNAs differentially expressed in active UC as compared with normal
controls. A list of the 51 significantly differentially expressed miRNAs in active UC
vs. controls with their corresponding fold change (FC) values. A significant
miRNA has a false discovery rate (FDR),5% and FC.2. miRNAs that were also
significantly differentially expressed in active UC vs. inactive UC are indicated in
bold.
doi:10.1371/journal.pone.0116117.s006 (XLSX)
S3 Table. mRNAs differentially expressed in active UC as compared with normal
controls.
doi:10.1371/journal.pone.0116117.s007 (XLSX)
S4 Table. Selected inversely correlated significantly differentially expressed
miRNAs and their predicted target mRNAs. miRNAs belonging to the same
family are grouped together.
doi:10.1371/journal.pone.0116117.s008 (XLSX)
S5 Table. List of all 318 significantly inversely correlated miRNA-mRNA pairs.
doi:10.1371/journal.pone.0116117.s009 (XLSX)
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